Objective: The objective of this study is to assess whether antiretroviral therapy (ART) may diminish the effectiveness of hormonal contraceptive methods.
Introduction
Worldwide, a substantial unmet need for well tolerated, effective contraception remains, particularly in areas with a high HIV prevalence [1] . For HIV-infected women, contraception is important for their own health, for preventing mother-to-child HIV transmission and to control their fertility. For women using antiretroviral therapy (ART), concerns have been raised that some progestin-based contraceptive methods may be less effective when used with certain ARTagents. Specifically, it has been suggested that the nonnucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (NVP) and efavirenz (EFV), may accelerate the progestin metabolism through the cytochrome p450 pathway [2] . Studies of interactions between ART and contraceptive methods have been limited by short follow-up times, HIVuninfected populations and/or surrogate endpoints [3] . We sought to understand the effect of ART on contraceptive effectiveness, measured by the clinical endpoint of pregnancy, using prospectively collected data from over 5000 women with chronic HIV infection from East and Southern Africa.
Materials and methods

Study population
Data contributed by women in three prospective studies (Partners in Prevention HSV/HIV Transmission Study, Couples Observation Study and Partners PrEP Study) were combined for this analysis. Enrolment for these studies has previously been described [4] [5] [6] . In brief, 8640 HIV serodiscordant heterosexual couples from seven African countries (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, Zambia) were enrolled and followed between 2004 and 2013; overall, in 63% of couples, the seropositive partner was female. At enrolment, HIV-infected partners were not using ART; clinical and immunologic status was monitored during follow-up and ART was recommended according to national guidelines.
Demographic information was collected at enrolment; data on sexual behaviour, including contraceptive use and ART use, were collected quarterly. Tests for Trichomonas vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae were performed at baseline for all studies and annually in the Partners PrEP Study. CD4 þ cell counts were measured every 6 months; viral load was measured every 6 months in the Partners in Prevention HSV/HIV Prevention Study and Couples Observational Study and annually in the Partners PrEP Study. Condoms, hormonal and nonhormonal contraception were offered in all studies and contraceptive method use was self-reported at each visit; however, information regarding specific brands was not recorded. Pregnancy status was ascertained at each study visit; urine pregnancy tests were done as clinically indicated and quarterly in Partners in Prevention HSV/HIV Transmission Study. All women gave informed, written consent; these studies were approved by the University of Washington Human Subjects Review Committee and local ethics review boards associated with each study site.
Statistical analysis
For this analysis, only women who were HIV infected, 49 years of age or less and who contributed at least one follow-up visit were included. Months during which women reported diaphragms, intrauterine devices (IUDs) tubal ligation or hysterectomies for contraception were excluded; this included 5 person-years on diaphragm, 120 person-years on IUD and 520 person-years on tubal ligation/hysterectomy, with only one pregnancy (on IUD). The primary endpoint was incident pregnancy. The first visit at which a woman was pregnant, determined by positive pregnancy test and the date of her last menstrual period, was classified as the incident event; visits while pregnant were censored and women returned to the risk set at the first visit after each pregnancy ended. The primary exposure was hormonal contraceptive use, defined as implant, injectable, oral contraceptives or none. ART use at each study visit was analysed as an effect modifier and the rate of incident pregnancy was calculated for each contraceptive-ARTuse stratum. Thus, when a pregnancy was first detected at a study visit, contraceptive and ART exposure were reported at that same visit, as data collection for those exposures referred to the period when the pregnancy began. Interaction terms between each of the three contraceptive methods and ART use were included in multivariable Cox proportional hazards models, with an Andersen-Gill extension allowing for repeated events [7] . P values for these interactions were determined by likelihood ratio tests, with no hormonal contraception and no ARTuse as the reference category. Age, CD4 þ cell count, site and study were included a priori; other potential covariates were tested and only sexual frequency and condomless sex were added to the model. Subgroup analyses were done, restricted to women using NVP or EFV (with no ART use as the reference group). All analyses were conducted in SAS 9.4 (Cary, North Carolina, USA).
Results
Among the 5153 women included in this analysis, 54% were under 30 years old at baseline and 51% had CD4 þ cell counts at least 500 cells/ml at enrolment (Table 1) . A total of 9266 person-years were accrued and median follow-up time was 1.8 years [interquartile range (IQR) 1.2-2.3]. During follow-up, 24% of women became pregnant and 31% ever used ART, including 23% who used NVP and 5% who used EFV. Also during follow-up, 9% of women ever used implants, 40% ever used injectable contraception and 14% ever used oral contraceptives; for women who used implants at baseline, 82% of subsequent visits had continued use, while for injectables continuation was 70% and for oral contraceptives it was 58%.
The overall pregnancy rate was 14.8 per 100 person-years. Women not using contraception but using ART had a lower pregnancy rate than those not using contraception and not using ART [13.2 vs. 22.5 per 100 person-years; aHR 0.62, 95% confidence interval (95% CI) 0.51-0.75, P < 0.001]. In a sensitivity analysis that excluded the first 6 months after each pregnancy, this association between ART use and pregnancy was attenuated (aHR 0.80, 95% CI 0.63-0.99, P ¼ 0.03), potentially indicating that this difference was due to a postpartum effect for women who had initiated ART during pregnancy.
Implants were highly effective in reducing incident pregnancy, with rates less than 1.5 per 100 person-years among those both on and not on ART ( Table 2) ; pregnancy incidences among implant users were more than 90% lower than among women not using contraception. There was no statistical difference between the effects of implants on pregnancy prevention for women using versus not using ART (interaction P ¼ 0.73). Both injectables and oral contraceptives also significantly reduced pregnancy risk compared with women not using contraception, although to a lesser extent than implants. For women using injectables, the reduction in pregnancy incidence was approximately 80%, and for oral contraceptives, the relative reduction was approximately 60%; neither of these effects differed significantly for women on ART versus not on ART.
NVP was the most common ART agent reported, with 1000 person-years of follow-up. The results among women using NVP were very similar to the overall analysis. Injectables reduced pregnancy by approximately 80% and oral contraceptives reduced pregnancy by approximately 60%; for both methods, the pregnancy prevention effects were not different when using versus not using NVP (interaction term P ¼ 0.80 for injectables and P ¼ 0.95 for oral contraceptives). There were no pregnancies among women using NVP and implants.
Approximately 200 person-years accrued from women using EFV. The pregnancy prevention point estimates for women using EFV were lower for all types of progestinbased contraception: implants reduced pregnancy incidence by approximately 60%, injectables by 70% and oral contraceptives by only 15%. None of these reductions in incidence were statistically significant, in part likely because of the small sample size; there were also no statistically significant interactions for EFV use with any contraceptive method compared with women not using ART. For women using oral contraceptives with EFV, the point estimate for the pregnancy rate was double that of those using NVP. For women using implant, a single pregnancy occurred during 16.7 person-years of concurrent use with EFV, at 11 months postinsertion of the implant.
Discussion
In this analysis of a large, prospective database from African women living with HIV, we found that hormonal contraceptives were effective in reducing pregnancy, including for women using ART. Implants were the most effective at reducing pregnancy incidence, by more than 90%, and we found no evidence that ART use in general diminished implant effectiveness. Injectable and oral methods were also effective, and their effectiveness did not differ significantly by ART use. All hormonal methods had point estimates suggesting lesser effectiveness among EFV users, although the sample size for analyses limited to EFV users was small.
Our analysis is consistent with the existing literature. Most pharmacokinetic and observational studies of NVP have found no difference in progesterone levels nor contraceptive effectiveness with progestin-based contraception [8] [9] [10] [11] [12] [13] [14] [15] . The literature regarding EFV is more mixed. Studies have found no effect of EFV on progesterone levels when using depot medroxyprogesterone acetate (DMPA) [8, 10, 16] , but significantly lower progesterone levels among implant users [15, [17] [18] [19] , along with contraceptive failure rates up to 15% among levonorgestrel implant users [20] [21] [22] . Evidence regarding EFV and oral contraceptives is very limited, suggesting lower progesterone levels but not necessarily increased ovulation on EFV [13, 23, 24] . The existing evidence has led at least one national health department in Africa to recommend against implant use for women on EFV [25] . However, a recent retrospective analysis found that implants were more effective at pregnancy prevention than injectables for women using NVP or EFV [26] . Likewise, in the present analysis, contraceptive failures were seen on all methods, although they were rare for women using implants.
Among women not using contraception, we found that ART use was associated with lower pregnancy incidence; other studies have found that ARTuse was associated with either an increase or no difference in pregnancy [27, 28] . However, this difference would not affect the significance of the interaction terms presented, as the primary comparison was pregnancy incidence for women using versus not using contraception, separately for those on and not on ART. In a sensitivity analysis that excluded 6 months after each pregnancy, the association between ART use and pregnancy was attenuated, suggesting potential confounding with PMTCT and reduced fertility in the postpartum period. Furthermore, the estimated hazard ratios and significance of the interaction terms were not changed. In addition, there may have been residual confounding due to behavioural and health differences between women who initiate ART versus those not yet starting ART.
Limitations of this study include that ascertainment of ART use, contraceptive use and important potential confounders, such as sexual behaviour, were based on self-report. We are unable to further distinguish specific progestin-based contraceptive methods, although DMPA was the predominant form of injectable, levonorgestrel was the most common implant and combined pills were the most common oral contraceptives available at the study sites. Duration of ART and hormonal contraception use were not examined and may be of interest. This study benefits from a large sample size from 2004 to 2013, with over 9000 person-years of follow-up; however, time on EFV was limited. Detailed information was collected to date the beginning of each pregnancy.
This longitudinal study of incident pregnancies suggests that hormonal contraceptive methods remain effective for HIV-infected women who are using ART, including NNRTIs. Implants, which have the lowest adherence requirements out of these three methods, showed the greatest reduction on pregnancy rates, including for women concurrently using ART. Pregnancy incidence was highest for women using oral contraceptives, followed by injectables, with failure rates considerably higher than in ideal use settings, possibly relating to inconsistent or incorrect use. As national policies evaluate the potential pharmacokinetic interactions between ART and hormonal contraception, prospective studies such as this, which comparatively evaluate the real-world effectiveness of contraceptive methods, are essential. 
